Pfizer Stock Price, News & Analysis

Pfizer and BioNTech announce the FDA's Emergency Use Authorization (EUA) for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as a third 3-µg dose in the primary vaccination series for children aged 6 months to 4 years. Given the urgent need due to rising COVID-19 cases and respiratory illnesses in young children, vaccine doses will ship immediately upon CDC recommendation. The EUA is supported by clinical data and aims to enhance protection against severe illness in this age group.

Pfizer (NYSE: PFE) announced that the FDA has accepted its Biologics License Application (BLA) for RSV vaccine candidate RSVpreF for individuals aged 60 and older. The priority review status shortens the review process by four months, aiming for a decision by May 2023. This follows the FDA's Breakthrough Therapy Designation granted in March 2022. RSV causes significant morbidity among older adults, with 60,000-120,000 hospitalizations annually in the U.S. The vaccine candidate is supported by a Phase 3 trial involving approximately 37,000 participants, showing promise in addressing this public health challenge.

Pfizer (NYSE: PFE) announced a collaboration with Clear Creek Bio to develop novel papain-like protease (PLpro) inhibitors aimed at treating COVID-19. This partnership will enhance Pfizer's existing COVID-19 product line with potential oral antivirals targeting various viral mechanisms. Both companies will work on identifying a PLpro candidate for clinical development, with Pfizer taking charge of commercialization. Clear Creek will receive an undisclosed upfront payment and potential future royalties based on product sales.

Pfizer Inc. (NYSE: PFE) invites investors to its Near-Term Launches + High-Value Pipeline Day on December 12, 2022, from 1:00 p.m. EST to 6:00 p.m. EST. The event will showcase potential product launches and pipeline programs that are expected to drive revenue growth through 2030. The live video webcast will be accessible via Pfizer's investor website, with an opportunity for audience questions during the Q&A sessions. A transcript and replay of the event will be available online within 24 hours.

On World AIDS Day, the Health Action Alliance and ViiV Healthcare launched the U.S. Business Action to End HIV, a coalition of businesses aimed at eliminating HIV in the U.S. by 2030. Founding members include major companies like CVS Health, Gilead Sciences, and Walgreens. The initiative aligns with the National HIV/AIDS Strategy and seeks to mobilize private sector support to improve access to HIV prevention and treatment. More than 1.2 million people in the U.S. live with HIV, with nearly 35,000 new cases annually.

ViiV Healthcare released survey data on World AIDS Day 2022, highlighting persistent stigma surrounding HIV. Conducted by Opinium, the survey revealed that 74% of respondents believe negative perceptions still exist, with 25% opposing discussions about HIV in workplaces. While 76% feel comfortable with physical contact with those living with HIV, only 50% would date someone with the virus. The campaign, ‘HIV in View’, aims to combat stigma through public awareness and advocacy for non-stigmatising language.

Pfizer Inc. (NYSE: PFE) invites investors and the public to join a webcast featuring CFO David Denton at the Wolfe Research Healthcare Conference on November 18, 2022, at 8:45 a.m. EST. Investors can access the webcast at www.pfizer.com/investors, where information on registration will also be available. A transcript and replay will be accessible on Pfizer's site within 24 hours post-event for at least 90 days. Pfizer focuses on innovative therapies, improving patients' lives, and enhancing healthcare access globally.

Pfizer and BioNTech announced robust results from a Phase 2/3 clinical trial for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine. A 30-µg booster significantly increased neutralizing antibody titers—13.2-fold in adults over 55 and 9.5-fold for those aged 18 to 55 compared to the original vaccine. The safety profile remains favorable, similar to the original vaccine. These findings suggest enhanced protection against Omicron variants and support ongoing evaluations of the vaccine's effectiveness against emerging strains.

Pfizer's investigational cancer immunotherapy, elranatamab, has received Breakthrough Therapy Designation from the FDA for treating relapsed or refractory multiple myeloma (RRMM). This designation is based on promising results from the Phase 2 MagnetisMM-3 study, which reported a 61% overall response rate after a median follow-up of 6.8 months. The therapy could provide significant advantages over existing treatments.

Elranatamab is designed to engage cancer and T-cells simultaneously, offering a novel approach to treatment.